NYSE$ANVS
Annovis Bio · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Annovis Bio reported Q1 2025 a net loss of $5.5M, diluted EPS of $-0.32.
For Q1 2025, Annovis Bio reported net loss was $5.5M, diluted EPS was $-0.32. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $5.5M.
- Diluted EPS $-0.32.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Annovis Bio · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.
Tailwinds
- Pipeline readouts and partnership economics.
- Cash balance supports near-term development plans.
Headwinds
- Operating losses and trial risk until commercialization.
- Financing markets and competition affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.9%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+8.0%
Avg return
30 days after
35%
9 / 26 earnings
Positive
+41.0%
Q1 2024
Best reaction
-68.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -7.0% | -16.8% | |
| Q4 2025 | -3.1% | -8.1% | -37.1% | |
| Q3 2025 | +15.5% | +43.6% | +95.7% | |
| Q2 2025 | -1.4% | -2.8% | -15.2% | |
| Q1 2025 | +6.6% | +18.9% | +66.3% | |
| Q4 2024 | -7.1% | -8.5% | +14.2% | |
| Q3 2024 | -7.6% | -16.2% | -27.0% | |
| Q2 2024 | +9.9% | +14.9% | +3.2% | |
| Q1 2024 | +41.0% | +40.1% | +2.5% | |
| Q4 2023 | -6.1% | -6.7% | -48.7% | |
| Q3 2023 | -0.3% | +3.1% | +76.9% | |
| Q2 2023 | -1.7% | -3.5% | -17.0% | |
| Q1 2023 | -5.8% | -8.5% | -9.1% | |
| Q4 2022 | -22.5% | -18.2% | -4.9% | |
| Q3 2022 | -4.1% | +1.1% | -3.3% | |
| Q2 2022 | +5.9% | +10.1% | -7.1% | |
| Q1 2022 | +9.9% | -3.3% | -1.3% | |
| Q4 2021 | -7.6% | -13.5% | +1.0% | |
| Q3 2021 | -0.9% | +21.3% | -30.4% | |
| Q2 2021 | -68.5% | -65.8% | -66.2% | |
| Q1 2021 | +5.8% | +30.1% | +188.3% | |
| Q4 2020 | -10.3% | -9.7% | -0.5% | |
| Q3 2020 | +3.8% | -1.1% | +28.7% | |
| Q2 2020 | -0.3% | -2.2% | -20.6% | |
| Q1 2020 | -0.8% | -3.0% | +21.9% | |
| Q4 2019 | +6.5% | +0.9% | +14.1% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro